17 September 2025
Update on the RESOLUTE Phase III trial for Fasenra in chronic obstructive pulmonary disease The RESOLUTE Phase III trial of AstraZeneca’s Fasenra (benralizumab), despite showing numerical improvement, did…
Advanced Medical Solutions Group plc (“AMS” or the “Group”) Interim results for the six months ended 30 June 2025 ~ H1 delivering high quality…
16 September 2025
HARWORTH GROUP PLC (‘Harworth’ or the ‘Group’ or the ‘Company’) Half Year Results for the six months ended 30 June 2025 Strong momentum underpins…
NWF Group PLC 16 September 2025 NWF Group PLC NWF Group plc: AGM Statement and Trading Update At the Annual General Meeting of NWF…
MJ Gleeson plc (“Gleeson”, “the Group” or “the Company”) Audited results for the year ended 30 June 2025 (“FY2025”) Full year outturn in line…
15 September 2025
M.P. EVANS GROUP PLC (“Company” or “M.P. Evans”) INTERIM RESULTS M.P. Evans, a producer of sustainable Indonesian palm oil, announces its unaudited interim results…
HgCAPITAL TRUST PLC INTERIM RESULTS FOR THE PERIOD ENDED 30 JUNE 2025 CONTINUED STRONG TRADING GROWTH AND TRANSACTION ACTIVITY IN A CHALLENGING MACRO ENVIRONMENT…
12 September 2025
Euronext celebrates recognition of strong market performance and shareholder value creation since the IPO in 2014 Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris…